ArticleFrontiers in oncology2025
Molecular and histopathological landscape of 131 meningiomas: a retrospective institutional study with insights from cIMPACT-NOW.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multidisciplinary management of meningiomas in the era of precision oncology.Nature reviews. Clinical oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prognostication in meningiomas has traditionally relied on histopathological grading, which has inherent limitations, including interobserver variability, intratumoral heterogeneity, and inconsistent correlation with clinical behavior. While molecular profiling enhances diagnostic precision and risk stratification, it is not yet routinely adopted in clinical practice. To date, no molecular data on meningiomas have been published from our country. This study aims to address this gap by characterizing the molecular landscape of meningiomas at our institution, incorporating insights from recent cIMPACT-NOW updates. Methods: We retrospectively analyzed consecutive 131 meningiomas that underwent molecular sequencing at our institution between 2021 and 2023. Tumors were classified according to the latest WHO criteria. Next-generation sequencing (NGS) was performed using the Oncomine Comprehensive Assay, a targeted panel for solid tumors. Molecular findings were correlated with clinicopathological parameters. Results: The cohort included 84 females and 47 males (median age: 51 years; range: 2-79). Tumor locations included the cerebral convexity (45.8%), skull base (38.2%), posterior fossa (3.1%), and spine (5.3%), with 7.6% being multifocal. CNS WHO grade 2 tumors were most common (58%), followed by grade 1 (35%) and grade 3 (7%). Conclusion: This study provides regional insight into the molecular landscape of meningiomas in our population. While routine molecular profiling adds value to classification and prognostication, broader implementation may be limited by cost and panel coverage constraints.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.